OLIGOMENORRHEA AND AMENORRHEA IN POLYCYSTIC OVARY SYNDROME: A RETROSPECTIVE ANALYSIS OF CLINICAL-METABOLIC PHENOTYPES
DOI:
https://doi.org/10.5281/zenodo.23642985Keywords:
polycystic ovary syndrome, oligomenorrhea, amenorrhea, HOMA-IR, LH/FSH ratio, insulin resistanceAbstract
Background. Menstrual dysfunction in polycystic ovary syndrome (PCOS) may be associated with metabolic and hormonal abnormalities. Comparing the clinical phenotypes of oligomenorrhea and amenorrhea may help characterize metabolic differences of practical relevance. Objective. To compare clinical, metabolic, and hormonal parameters in women with PCOS presenting with oligomenorrhea and amenorrhea. Materials and methods. A retrospective analysis included 79 women diagnosed with PCOS. Oligomenorrhea was recorded in 44 patients and amenorrhea in 34 patients. Age, body mass index (BMI), fasting glucose, insulin, HbA1c, HOMA-IR, FSH, LH, prolactin, total testosterone, and the LH/FSH ratio were assessed. Results. No statistically significant differences were found between the oligomenorrhea and amenorrhea groups in BMI, glucose, insulin, HbA1c, HOMA-IR, FSH, LH, or prolactin. The LH/FSH ratio was 2.29 (1.74–2.98) in the oligomenorrhea group and 1.96 (1.58–2.75) in the amenorrhea group (p=0.302). The proportions of patients with HOMA-IR ≥2.5 were 54.5% and 50.0%, respectively (p=0.820). Conclusion. In women with PCOS, oligomenorrhea and amenorrhea did not differ significantly with respect to the main metabolic and hormonal parameters. The LH/FSH ratio may be assessed as an additional hormonal marker.References
1. Teede, H. J., Tay, C. T., Laven, J. J. E., Dokras, A., Moran, L. J., Piltonen, T. T., et al. (2023). Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. Journal of Clinical Endocrinology & Metabolism, 108(10), 2447–2469.
2. Dason, E. S., Lee, J. Y., & Sagle, M. A. (2024). Diagnosis and management of polycystic ovarian syndrome. CMAJ. 2024;196(3):E85–E94.
3. Li, X., et al. (2024). Association of severity of menstrual dysfunction with cardiometabolic risk markers among women with polycystic ovary syndrome. Acta Obstetricia et Gynecologica Scandinavica. 2024.
4. Niu, J., et al. (2023). Association between insulin resistance and abnormal menstrual cycle in Chinese patients with polycystic ovary syndrome. Journal of Ovarian Research. 2023;16:45.
5. Wen, X., Wang, L. W., & Bai, E. (2024). Metabolic characteristics of different phenotypes in reproductive-aged women with polycystic ovary syndrome. Frontiers in Endocrinology. 2024;15:1370578.
6. Rahmatnezhad, L., et al. (2023). Association of insulin resistance with polycystic ovary syndrome phenotypes and patients’ characteristics: a cross-sectional study in Iran. Scientific Reports. 2023.
7. Prosperi, S., et al. (2025). Insulin resistance, metabolic syndrome and polycystic ovaries: an intriguing conundrum. Frontiers in Endocrinology. 2025.
8. Soares-Jr, J. M., et al. (2023). Influence of Phenotypes on the Metabolic Syndrome of Women with Polycystic Ovary Syndrome over a Six-Year Follow-Up in Brazil. Biomedicines. 2023;11(12):3262. 3262.
9. Pratama, G., & Wiweko, B. (2024). Asmarinah, Widyahening I.S., Andraini T., Bayuaji H., Hestiantoro A. Mechanism of elevated LH/FSH ratio in lean PCOS revisited: a path analysis. Scientific Reports. 2024;14:8229.
10. Zheng, C., et al. (2025). Analyzing and evaluating the metabolic and endocrine characteristics of lean and obese polycystic ovary syndrome: a systematic review and meta-analysis. Frontiers in Endocrinology. 2025.
11. Joham, A. E., Norman, R. J., Stener-Victorin, E., Legro, R. S., Franks, S., Moran, L. J., et al. (2022). Polycystic ovary syndrome. Lancet Diabetes & Endocrinology, 10(9), 668–680. https://doi.org/10.1016/S2213-8587(22)00163-2
12. Mansour, A., et al. (2023). Risk factors for insulin resistance related to polycystic ovarian syndrome in Iranian population. Scientific Reports. 2023;13. doi:10.1038/s41598-023-37513-2. 41598–023. https://doi.org/10.1038/s41598-023-37513-2
13. Szkodziak, P., et al. (2025). Insulin resistance in polycystic ovary syndrome phenotypes and the vicious cycle model in its etiology. Scientific Reports. 2025. doi:10.1038/s41598-025-26718-2. 41598–025. https://doi.org/10.1038/s41598-025-26718-2
14. Morshed, M. S., et al. (2025). Association of adiposity indices with insulin resistance among women with polycystic ovary syndrome. Clinical and Experimental Reproductive Medicine. 2025. doi:10.5653/cerm.2024.07388. https://doi.org/10.5653/cerm.2024.07388
15. Feng, X., et al. (2024). Efficacy and safety of Cangfu Daotan decoction as an adjuvant treatment of Diane-35 for polycystic ovary syndrome: A systematic review and meta-analysis. Heliyon. 2024;10:e36959. doi:10.1016/j. heliyon.2024.e36959. A systematic review and meta-analysis. Heliyon. https://doi.org/10.1016/j
16. Ren, X., et al. (2024). Different supplements improve insulin resistance, hormonal functions, and oxidative stress on overweight and obese women with polycystic ovary syndrome: a systematic review and meta-analysis. Frontiers in Endocrinology. 2024;15:1464959. doi:10.3389/fendo.2024.1464959. https://doi.org/10.3389/fendo.2024.1464959
17. Bo, Y., Zhao, J., Liu, C., et al. (2025). Comparative efficacy of pharmacological interventions on metabolic and hormonal outcomes in polycystic ovary syndrome: a network meta-analysis of randomized controlled trials. BMC Women’s Health. 2025;25:64. doi:10.1186/s12905-025-03594-6. 12905–025. https://doi.org/10.1186/s12905-025-03594-6
18. Melin, J. M., et al. (2024). Effects of different insulin sensitisers in the management of polycystic ovary syndrome: a systematic review and meta-analysis. Clinical Endocrinology. 2024. doi:10.1111/cen.14983. https://doi.org/10.1111/cen.14983
19. Scragg, J., Hobson, A., Willis, L., et al. (2024). Effect of weight loss interventions on the symptomatic burden and biomarkers of polycystic ovary syndrome: a systematic review of randomized controlled trials. Annals of Internal Medicine. 2024;177(12). doi:10.7326/M23-3179. https://doi.org/10.7326/M23-3179
20. Goldberg, A., Graca, S., Liu, J., Rao, V., Witchel, S. F., Pena, A., et al. (2023). Anti-obesity pharmacological agents for polycystic ovary syndrome: a systematic review and meta-analysis to inform the 2023 international evidence-based guideline. Obesity Reviews. 2024;25(5):e13704. doi:10.1111/obr.13704. https://doi.org/10.1111/obr.13704
21. Muslim, M. Z. M. (2024). Mohammed Jelani A., Shafii N., Yaacob N.M., Che Soh N.A.A., Ibrahim H.A. Correlation between anti-mullerian hormone with insulin resistance in polycystic ovarian syndrome: a systematic review and meta-analysis. Journal of Ovarian Research. 2024;17:106. doi:10.1186/s13048-024-01436-x. 13048–024. https://doi.org/10.1186/s13048-024-01436-x
Downloads
Published
How to Cite
Issue
Section
